^
Association details:
| Biomarker: | ALK translocation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Excerpt:
...The objective response rate (ORR) as a measure of anti-tumor efficacy of oral PF-02341066 in participants with advanced NSCLC with an ALK gene translocation or inversion after failure of at least one line of chemotherapy.`...
Trial ID:
Source:
Title:
A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer
Excerpt:
...- Positive for translocation or inversion events involving the ALK gene locus...
Trial ID:
More C2 evidence
Source:
Title:
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1
Excerpt:
...- unresectable locally advanced or metastatic malignant tumor of any histological type (but NSCLC with an ALK translocation) and...
Trial ID:
Source:
Title:
Long Term Safety Observation of Crizotinib in Chinese NSCLC Population
Excerpt:
...All SAEs，all AEs leading to permanent treatment discontinuation, and all grades 3-5 AEs as assessed by CTCAE v4.03`long term safety of crizotinib in patients with advanced NSCLC harboring a translocation or inversion of the ALK gene or ROS1 gene locus...
Trial ID:
Source:
Title:
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Excerpt:
...- Positive for translocation or inversion events involving the ALK gene locus (e.g....
Trial ID:
Source:
Title:
Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
Excerpt:
...Real incidence of ALK-positive NSCLC in Spain`Incidence of ALK-positive NSCLC in Spain`Efficacy in terms of PFS of Crizotinib in patients with advanced ALK+ and ROS1 translocation NSCLC`Progression Free Survival [PFS]...
Trial ID:
Source:
Title:
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
Excerpt:
...- Negative for translocation or inversion events involving the ALK gene...
Trial ID:
Source:
Title:
Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus
Excerpt:
...- Histologically proven diagnosis of NSCLC at MSKCC Tumor positive for a translocation or inversion event involving the ALK gene locus -...
Trial ID:
Source:
Title:
A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
Excerpt:
...- Positive for translocation or inversion events involving the ALK gene locus....
Trial ID:
Source:
Title:
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
Excerpt:
...- Positive for translocation or inversion events involving the ALK gene locus...
Trial ID:
Less C2 evidence
Source:
Title:
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)
Published date:
09/19/2022
Excerpt:
This is an observational prospective and retrospective cohort study to determine the incidence of ALK translocations and to analyze the effectiveness and safety of crizotinib in a real-world setting....The ORR was 59.3% and the median duration of response was 13.5 months (IQR, 5.3–26.2). The median PFS was 15.8 months (95% CI, 11.8–22.3) and the median OS was 46.5 months, with 53 patients (58.2%) still alive at data cut-off date.
DOI:
https://doi.org/10.1016/j.lungcan.2022.09.010
Trial ID:
